Lataa...
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...
Tallennettuna:
| Julkaisussa: | Cancer Sci |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540985/ https://ncbi.nlm.nih.gov/pubmed/32735723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14593 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|